Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia

Orphanet Journal of Rare Diseases

Volumn 5, Issue 1, 2010, Pages

  Grievink, Hilbert ^a   Stowell, Kathryn M ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; MESSENGER RNA; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; LYMPHOBLASTOID CELL LINE; MALIGNANT HYPERTHERMIA; NUCLEOTIDE SEQUENCE; PENETRANCE; PHENOTYPE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RNA STABILITY; SKELETAL MUSCLE; WILD TYPE; CELL CULTURE; CELL LINE; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE; CELLS, CULTURED; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA STABILITY; RNA, MESSENGER; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 77952300810     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-5-10     Document Type: Article

References (35)

1. Anaesthetics deaths in family. M Denborough R Lovell, Lancet 1960 ii 45 10.1016/S0140-6736(60)92690-8
2. Malignant hyperpyrexia and sudden infant death. M Denborough, Aust N Z J Obstet Gynaecol 1991 31 91 1872787
3. Malignant hyperthermia. M Denborough, Lancet 1998 352 1131 1136 10.1016/S0140-6736(98)03078-5 9798607
4. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. N Monnier R Krivosic-Horber JF Payen G Kozak-Ribbens Y Nivoche P Adnet H Reyford J Lunardi, Anesthesiology 2002 97 1067 1074 10.1097/00000542-200211000-00007 12411788
5. Malignant hyperthermia. DH MacLennan MS Phillips, Science 1992 256 789 794 10.1126/science.1589759 1589759
6. A clinical grading scale to predict malignant hyperthermia susceptibility. MG Larach AR Localio GC Allen MA Denborough FR Ellis GA Gronert RF Kaplan SM Muldoon TE Nelson H Ording, et al. Anesthesiology 1994 80 771 779 10.1097/00000542-199404000-00008 8024130
7. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. DH MacLennan C Duff F Zorzato J Fujii M Phillips RG Korneluk W Frodis BA Britt RG Worton, Nature 1990 343 559 561 10.1038/343559a0 1967823
8. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. TV McCarthy JM Healy JJ Heffron M Lehane T Deufel F Lehmann-Horn M Farrall K Johnson, Nature 1990 343 562 564 10.1038/343562a0 2300206
9. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth 1984 56 1267 1269 10.1093/bja/56.11.1267 6487446
10. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206 Met (C6617T) mutation. M Wehner H Rueffert F Koenig J Neuhaus D Olthoff, Clin Genet 2002 62 135 146 10.1034/j.1399-0004.2002. 620206.x 12220451
11. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. AA Anderson RL Brown B Polster N Pollock KM Stowell, Anesthesiology 2008 108 208 215 10.1097/01.anes.0000299431.81267.3e 18212565
12. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Tong H Oyamada N Demaurex S Grinstein TV McCarthy DH MacLennan, J Biol Chem 1997 272 26332 26339 10.1074/jbc.272.42.26332 9334205
13. Increasing the number of diagnostic mutations in malignant hyperthermia. S Levano M Vukcevic M Singer A Matter S Treves A Urwyler T Girard, Hum Mutat 2009 30 590 598 10.1002/humu.20878 19191329
14. Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the LightCycler 480 System. H Grievink KM Stowell, Anal Biochem 2008 374 396 404 10.1016/j.ab.2007.11.019 18082125
15. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. T Deufel R Sudbrak Y Feist B Rubsam I Du Chesne KL Schafer N Roewer T Grimm F Lehmann-Horn EJ Hartung, et al. Am J Hum Genet 1995 56 1334 1342 7762556
16. A case of discordance between genotype and phenotype in a malignant hyperthermia family. G Fortunato A Carsana N Tinto V Brancadoro G Canfora F Salvatore, Eur J Hum Genet 1999 7 415 420 10.1038/sj.ejhg.5200314 10352931
17. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? RL Robinson MJ Anetseder V Brancadoro C van Broekhoven A Carsana K Censier G Fortunato T Girard L Heytens PM Hopkins, et al. Eur J Hum Genet 2003 11 342 348 10.1038/sj.ejhg.5200964 12700608
18. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. KD Serfas D Bose L Patel K Wrogemann MS Phillips DH MacLennan CR Greenberg, Anesthesiology 1996 84 322 329 10.1097/00000542-199602000-00009 8602662
19. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. T Girard A Urwyler K Censier CR Mueller F Zorzato S Treves, Hum Mutat 2001 18 357 358 10.1002/humu.1203 11668625
20. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. T Girard S Treves K Censier CR Mueller F Zorzato A Urwyler, Br J Anaesth 2002 89 571 579 10.1093/bja/aef237 12393358
21. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations. M Fiege F Wappler R Weisshorn M Ulrich Gerbershagen M Steinfath Am Schulte J Esch, Anesthesiology 2002 97 345 350 10.1097/00000542-200208000-00010 12151923
22. Detection of regulatory variation in mouse genes. CR Cowles JN Hirschhorn D Altshuler ES Lander, Nat Genet 2002 32 432 437 10.1038/ng992 12410233
23. Allelic variation in gene expression is common in the human genome. HS Lo Z Wang Y Hu HH Yang S Gere KH Buetow MP Lee, Genome Res 2003 13 1855 1862 10.1101/gr.885403 12902379
24. Allelic variation in human gene expression. H Yan W Yuan VE Velculescu B Vogelstein KW Kinzler, Science 2002 297 1143 10.1126/science.1072545 12183620
25. Improved PCR amplification of multiple specific alleles (PAMSA) using internally mismatched primers. R Okimoto JB Dodgson, Biotechniques 1996 21 20 26 8816228
26. A routine method for the establishment of permanent growing lymphoblastoid cell lines. H Neitzel, Hum Genet 1986 73 320 326 10.1007/BF00279094 3017841
27. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. S Germer MJ Holland R Higuchi, Genome Res 2000 10 258 266 10.1101/gr.10.2.258 10673283
28. A new mathematical model for relative quantification in real-time RT-PCR. MW Pfaffl, Nucleic Acids Res 2001 29 45 10.1093/nar/29.9.e45 11328886
29. Actinomycin and DNA transcription. HM Sobell, Proc Natl Acad Sci USA 1985 82 5328 5331 10.1073/pnas.82.16.5328 2410919
30. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. Y Zhang D Wang AD Johnson AC Papp W Sadee, J Biol Chem 2005 280 32618 32624 10.1074/jbc.M504942200 16046395
31. Simultaneous quantitative and allele-specific expression analysis with real competitive PCR. C Ding E Maier AA Roscher A Braun CR Cantor, BMC Genet 2004 5 8 10.1186/1471-2156-5-8 15128429
32. The relative position of RyR feet and DHPR tetrads in skeletal muscle. C Paolini F Protasi C Franzini-Armstrong, J Mol Biol 2004 342 145 153 10.1016/j.jmb.2004.07.035 15313613
33. Characterization of recessive RYR1 mutations in core myopathies. H Zhou N Yamaguchi L Xu Y Wang C Sewry H Jungbluth F Zorzato E Bertini F Muntoni G Meissner S Treves, Hum Mol Genet 2006 15 2791 2803 10.1093/hmg/ddl221 16940308
34. Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. H Zhou M Brockington H Jungbluth D Monk P Stanier CA Sewry GE Moore F Muntoni, Am J Hum Genet 2006 79 859 868 10.1086/508500 17033962 (Pubitemid 44763400)
35. Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility. RL Robinson D Carpenter PJ Halsall DE Iles P Booms D Steele PM Hopkins MA Shaw, Br J Anaesth 2009 103 2 220 5 10.1093/bja/aep108 19454545